Nucleome Therapeutics Overview
- Founded
-
2019
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$6.43M
- Investors
-
1
Nucleome Therapeutics General Information
Description
Developer of a therapeutics technology platform designed for the unique ability to connect disease-linked variants in the dark matter of the genome. The company platform creates high-resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling professionals to get genetically guided therapeutic to provide improved patient outcomes.
Contact Information
Website
www.nucleome.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Other Healthcare Technology Systems
Biotechnology
Primary Office
- BioEscalator The Innovation Building
- The Old Road Campus, Roosevelt Drive, Headington
- Oxford OX3 7FZ
- England, United Kingdom
Nucleome Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 08-Aug-2019 | $6.43M | 00.000 | 000.00 | Completed | Generating Revenue |
Nucleome Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A Ordinary | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Nucleome Therapeutics Executive Team (4)
Nucleome Therapeutics Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Danuta Jeziorska Ph.D | Nucleome Therapeutics | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
| James Davies | Nucleome Therapeutics | Co-Founder, Board Member & Board Observer | 000 0000 |
| James Hughes | Nucleome Therapeutics | Co-Founder & Board Member | 000 0000 |
| Jonathan Hepple Ph.D | Self | Board Member & OSI Advisor | 000 0000 |
| Matthew Carpenter Ph.D | Self | Board Observer | 000 0000 |
Nucleome Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Nucleome Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Oxford Science Enterprises | University | Minority | 000 0000 | 000000 0 |